Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | TACR2 | P21452 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441836 | 0.86 | CCR1 (0.60) | CCR1MDM2CHRM2CCR5 | |
| SCHEMBL441837 | 0.86 | CCR1 (0.60) | CCR1MDM2CHRM2CCR5 | |
| SCHEMBL6363059 | 0.85 | CCR1 (0.39) | CCR1 | |
| SCHEMBL6362657 | 0.85 | CCR1 (0.38) | CCR1TP53CHRM2CCR5 | |
| SCHEMBL7733512 | 0.83 | CCR1 (0.42) | CCR1MDM2TP53CHRM2CCR5 | |
| SCHEMBL7733509 | 0.83 | CCR1 (0.42) | CCR1MDM2TP53CHRM2CCR5 | |
| SCHEMBL6363775 | 0.80 | CCR1 (0.35) | CCR1CHRM2CCR5 | |
| SCHEMBL6363771 | 0.80 | CCR1 (0.35) | CCR1CHRM2CCR5 | |
| SCHEMBL6360664 | 0.79 | CCR1 (0.36) | CCR1DRD3 | |
| SCHEMBL1323821 | 0.76 | CCR1 (0.35) | CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070549-A1 | Chemokine receptor antagonists and methods of use thereof | ACKR3, CXCR2, CCL11 | CCR1 4/4885DRD3 3541/4885MDM2 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.